Year All2024202320222021202020192018201720162015 Multiple Programs Featuring Poseida Therapeutics’ Advanced CAR-T Therapies Presented at American Society of Hematology 2017 Annual Meeting December 11, 2017 Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101 at the American Association for Cancer Research Prostate Cancer Meeting December 5, 2017 Poseida Therapeutics Presents on the Development of Allogeneic and Autologous BCMA-Specific CAR-T Therapies at Precision: Blood Cancer Summit November 14, 2017 Poseida Therapeutics to Present anti-PSMA CAR-T Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting November 8, 2017 Poseida Awarded $19.8 Million CIRM Grant to Support Clinical Trial of P-BCMA-101, a T Stem Cell Memory CAR-T Therapy for Multiple Myeloma October 26, 2017 Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly Comprised of Stem Cell Memory T Cells, at the Prostate Cancer Foundation Annual Retreat October 5, 2017 Poseida Therapeutics Opens Enrollment in a Phase 1 Study of BCMA-Specific CAR-T Stem Cell Memory Therapy for Patients with Multiple Myeloma September 26, 2017 Poseida Therapeutics Presents Novel BCMA-Specific CAR-T Therapy at CAR-TCR Summit September 6, 2017 Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor” CAR-T Cells at American Society of Clinical Oncology Annual Meeting June 5, 2017 Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy May 22, 2017
Multiple Programs Featuring Poseida Therapeutics’ Advanced CAR-T Therapies Presented at American Society of Hematology 2017 Annual Meeting December 11, 2017
Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101 at the American Association for Cancer Research Prostate Cancer Meeting December 5, 2017
Poseida Therapeutics Presents on the Development of Allogeneic and Autologous BCMA-Specific CAR-T Therapies at Precision: Blood Cancer Summit November 14, 2017
Poseida Therapeutics to Present anti-PSMA CAR-T Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting November 8, 2017
Poseida Awarded $19.8 Million CIRM Grant to Support Clinical Trial of P-BCMA-101, a T Stem Cell Memory CAR-T Therapy for Multiple Myeloma October 26, 2017
Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly Comprised of Stem Cell Memory T Cells, at the Prostate Cancer Foundation Annual Retreat October 5, 2017
Poseida Therapeutics Opens Enrollment in a Phase 1 Study of BCMA-Specific CAR-T Stem Cell Memory Therapy for Patients with Multiple Myeloma September 26, 2017
Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor” CAR-T Cells at American Society of Clinical Oncology Annual Meeting June 5, 2017
Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy May 22, 2017